StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTR) in a research note published on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.

CUTR has been the topic of several other research reports. Stephens dropped their target price on Cutera from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Piper Sandler restated a “neutral” rating and set a $1.00 target price (down previously from $3.00) on shares of Cutera in a research report on Friday, August 9th.

Cutera Price Performance

NASDAQ:CUTR opened at $0.49 on Tuesday. The company has a market cap of $9.83 million, a P/E ratio of -0.07 and a beta of 1.35. The stock’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $1.10. Cutera has a 1 year low of $0.28 and a 1 year high of $4.97.

Institutional Investors Weigh In On Cutera

Several large investors have recently added to or reduced their stakes in CUTR. Bayesian Capital Management LP bought a new stake in Cutera during the first quarter valued at $33,000. Ground Swell Capital LLC bought a new stake in Cutera during the second quarter valued at $37,000. Squarepoint Ops LLC boosted its stake in Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the period. Finally, Bank of Montreal Can boosted its stake in Cutera by 14.2% during the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the period. Institutional investors own 90.70% of the company’s stock.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.